Charles Schwab Investment Management Inc Passage Bio, Inc. Transaction History

Charles Schwab Investment Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.63 - $3.46 $48,137 - $102,180	-29,532 Reduced 12.97%	198,091 $468,000
Q1 2022 May 13, 2022	SELL	$2.66 - $6.49 $78,438 - $191,377	-29,488 Reduced 11.47%	227,623 $706,000
Q4 2021 Feb 11, 2022	BUY	$6.24 - $10.2 $39,923 - $65,259	6,398 Added 2.55%	257,111 $1.63 Million
Q3 2021 Nov 16, 2021	BUY	$9.73 - $15.52 $522,491 - $833,408	53,699 Added 27.26%	250,713 $2.5 Million
Q2 2021 Aug 16, 2021	BUY	$12.44 - $19.45 $252,855 - $395,340	20,326 Added 11.5%	197,014 $2.61 Million
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $778,902 - $1.43 Million	47,962 Added 37.26%	176,688 $3.09 Million
Q4 2020 Feb 16, 2021	BUY	$14.28 - $29.73 $366,996 - $764,061	25,700 Added 24.95%	128,726 $3.29 Million
Q3 2020 Nov 13, 2020	BUY	$12.39 - $26.15 $226,724 - $478,518	18,299 Added 21.6%	103,026 $1.35 Million
Q2 2020 Aug 14, 2020	BUY	$14.59 - $36.07 $1.24 Million - $3.06 Million	84,727 New	84,727 $2.32 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $31.6M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.